This company has been marked as potentially delisted and may not be actively trading. NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnership About Soleno Therapeutics Stock (NASDAQ:SLNO) Get Soleno Therapeutics alerts:Sign Up Key Stats Today's Range$53.01▼$53.0150-Day Range$30.05▼$53.0152-Week Range$29.43▼$90.32VolumeN/AAverage Volume1.75 million shsMarket Capitalization$2.76 billionP/E Ratio29.95Dividend YieldN/APrice Target$67.67Consensus RatingReduce Company Overview Soleno Therapeutics, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations. The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges. Soleno has completed multiple clinical trials of DCCR in adults and adolescents with PWS, evaluating its effects on hyperphagia, body composition and metabolic parameters. In addition to PWS, Soleno is advancing a proprietary formulation called SEZ982 for the treatment of phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare inherited condition that leads to multi-systemic impairment due to deficient protein glycosylation. Since its inception, Soleno has built a development pipeline rooted in rigorous translational research and active engagement with patient advocacy communities. The company works closely with academic collaborators and clinical centers of excellence across North America and Europe to design studies that address the full spectrum of disease manifestations. Soleno’s team combines expertise in drug formulation, clinical trial execution and regulatory strategy to expedite the path from laboratory discovery to potential market approval. Led by an experienced management team with deep backgrounds in biotech development and commercialization, Soleno continues to expand its scientific capabilities and prepare for potential regulatory submissions. The company maintains strategic partnerships and seeks to broaden its portfolio by identifying additional rare disease opportunities where small‐molecule therapies can deliver meaningful clinical outcomes. Through a patient-focused model, Soleno aims to bring new treatment options to communities with high unmet medical needs.AI Generated. May Contain Errors. Read More Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SLNO Stock News HeadlinesKuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law FirmSeptember 2, 2026 | prnewswire.comSLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens BermanMay 11, 2026 | prnewswire.comBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges investors not to sell before hearing his 2027 prediction. He warns that by November 30th, Congress is set to make a move he believes will trigger a historic buying panic. Economists call the phenomenon a crack-up boom. Rickards is known for correctly predicting the biggest market shocks of the last 20 years. | Paradigm Press (Ad)Soleno Merger With Neurocrine Puts Profitability And Valuation In FocusMay 10, 2026 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNOMay 5, 2026 | globenewswire.comSLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class ActionMay 5, 2026 | prnewswire.comDEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of ShareholdersMay 5, 2026 | globenewswire.comSLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law FirmMay 5, 2026 | prnewswire.comSee More Headlines SLNO Stock Analysis - Frequently Asked Questions How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) posted its quarterly earnings data on Wednesday, February, 25th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16. The business earned $91.73 million during the quarter, compared to analyst estimates of $88.55 million. Soleno Therapeutics had a net margin of 33.70% and a trailing twelve-month return on equity of 22.85%. Read the conference call transcript. When did Soleno Therapeutics' stock split? Soleno Therapeutics's stock reverse split on Friday, August 26th 2022.The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Palantir Technologies (PLTR), Sorrento Therapeutics (SRNE), Tesla (TSLA) and TherapeuticsMD (TXMD). Company Calendar Today11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SLNO's financial health is in the Green zone, according to TradeSmith. SLNO has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SLNO CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees30Year Founded1999Price Target and Rating Average Price Target for Soleno Therapeutics$67.67 High Price Target$107.00 Low Price Target$53.00 Potential Upside/Downside+27.6%Consensus RatingReduce Rating Score (0-4)1.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$1.77 Trailing P/E Ratio29.95 Forward P/E Ratio9.89 P/E GrowthN/ANet Income$20.89 million Net Margins33.70% Pretax Margin34.94% Return on Equity22.85% Return on Assets18.25% Debt Debt-to-Equity Ratio0.10 Current Ratio5.62 Quick Ratio5.32 Sales & Book Value Annual Sales$285.01 million Price / Sales9.69 Cash Flow$0.43 per share Price / Cash Flow124.10 Book Value$9.51 per share Price / Book5.57Miscellaneous Outstanding Shares52,120,000Free Float48,784,000Market Cap$2.76 billion OptionableOptionable Beta-2.22 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:SLNO) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersA $247 tool for $7Bill Poulos is offering his $247 Instant Scanner for $7 in the Black Friday sale. It's one payment for a full ...Profits Run | SponsoredA Nasdaq drone company just landed a deal with a Philippine billionaire's groupA Nasdaq-listed drone company just signed an exclusive agreement with Prime Strategic Holdings, part of billio...The Tomorrow Investor | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredBuy Stocks… A Crash is ComingThink stocks are expensive and a crash is coming? Economist Jim Rickards says you're right, but he urges inves...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.